G-1 (CAS 881639-98-1): Advancing GPR30 Agonist Research in Cardiovascular and Cancer Biology

Introduction

The discovery of non-classical estrogen signaling pathways has revolutionized the understanding of hormone action in physiology and disease. Among these, the G protein-coupled estrogen receptor (GPR30/GPER1) has emerged as a critical mediator of rapid, membrane-initiated estrogen responses, distinct from the genomic effects orchestrated by nuclear estrogen receptors ERα and ERβ. G-1 (CAS 881639-98-1), a highly selective and potent GPR30 agonist, is a cornerstone tool for dissecting these pathways. This article provides a comprehensive, mechanistic, and translational exploration of G-1, focusing on its role in cardiovascular protection, inhibition of breast cancer cell migration, and the modulation of intracellular signaling—offering a perspective that extends beyond prior reviews by integrating recent mechanistic insights and translational models.

G-1: Chemical Properties and Selectivity

G-1 is a crystalline solid with a molecular weight of 412.28 and chemical formula C₂₁H₁₈BrNO₃. It is highly soluble in DMSO (≥41.2 mg/mL) but insoluble in water and ethanol, with recommended stock preparation at concentrations above 10 mM using warming and ultrasonic bath to enhance solubility. For experimental reproducibility, solutions should be stored at -20°C and are not intended for long-term storage.

The hallmark of G-1 is its exceptional selectivity for GPR30, binding with a Ki of approximately 11 nM, and negligible affinity for ERα and ERβ even at micromolar concentrations. This selectivity enables researchers to probe GPR30-mediated effects without confounding activation of classical estrogen receptors, making APExBIO's G-1 (B5455) an indispensable reagent in cardiovascular, endocrine, and cancer biology research.

Mechanism of Action: GPR30 Activation and Intracellular Signaling

Distinct Pathways: Beyond Nuclear Estrogen Receptors

GPR30 is primarily localized to the endoplasmic reticulum, where it mediates rapid, non-genomic signaling upon ligand binding. Activation of GPR30 by G-1 triggers multiple intracellular cascades:

• Intracellular Calcium Signaling via GPR30: G-1 induces a swift increase in intracellular calcium concentrations (EC₅₀ = 2 nM), which is pivotal for rapid cellular responses, including modulation of cytoskeletal dynamics and gene transcription.
• GPR30-Mediated PI3K Signaling Pathway: G-1 stimulates nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in a PI3K-dependent manner, influencing cell survival, metabolism, and motility.

These pathways collectively underpin the physiological and pathophysiological effects of GPR30 activation—distinct from the slower, gene transcription-driven responses of ERα and ERβ. This mechanistic clarity enables researchers to attribute observed effects specifically to GPR30, as demonstrated by G-1’s minimal activity at other estrogen receptors.

Comparative Analysis with Alternative Methods and Prior Literature

Previous reviews and product summaries, such as "G-1 (CAS 881639-98-1): Unraveling GPR30 Signaling in Immunology", have focused on the immune-modulatory potential of G-1, offering advanced insights into PI3K and calcium signaling in immune normalization. By contrast, this article delves deeper into the dual application of G-1 in both cardiovascular and cancer research, emphasizing translational models and the unique advantages of G-1 over alternative GPR30 modulators.

Similarly, while "G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Signaling" highlights the role of G-1 in breast cancer cell migration and cardiac fibrosis, our analysis expands on the mechanistic basis of these effects and integrates new data regarding signaling specificity, in vivo validation, and the interplay with endoplasmic reticulum stress (ERS) pathways.

Advanced Applications in Cardiovascular Research

Cardiac Fibrosis Attenuation and Heart Failure Models

G-1’s ability to modulate GPR30 signaling has profound implications for cardiovascular health. In chronic heart failure models, particularly in female Sprague-Dawley rats with bilateral ovariectomy, long-term G-1 administration yields multiple cardioprotective effects:

• Reduction of brain natriuretic peptide (BNP) levels, a marker for cardiac stress and heart failure progression.
• Inhibition of cardiac fibrosis, thereby preserving myocardial architecture and function.
• Improvement of cardiac contractility, associated with normalization of β₁-adrenergic receptor expression and upregulation of β₂-adrenergic receptor expression.

These findings underscore the translational potential of G-1 in preclinical heart failure models and highlight its utility in studies of cardiac fibrosis attenuation. The specificity of G-1 for GPR30 ensures that observed effects are not confounded by ERα or ERβ activation, a limitation of earlier estrogenic compounds.

Integration with Endoplasmic Reticulum Stress Pathways

Recent mechanistic studies have linked GPR30 activation to the modulation of endoplasmic reticulum stress, an emerging therapeutic target in cardiovascular diseases. In a pivotal study (Wang et al., 2021), the role of GPR30 in mediating the beneficial effects of estradiol on splenic CD4⁺ T lymphocyte proliferation was elucidated. Here, G-1 administration was shown to normalize immune cell function following hemorrhagic shock, through inhibition of ERS. Notably, the salutary effects of estrogen were abrogated by GPR30 antagonism, underscoring the receptor’s centrality:

• ERS biomarkers (GRP78, ATF6) were upregulated following shock; G-1 reversed these changes, normalizing immune parameters.
• These effects were independent of ERβ, but required ERα and GPR30 activation, as shown by pharmacological antagonists and selective agonists.

This work not only highlights the translational relevance of G-1 in immune-cardiovascular interplay but also deepens the mechanistic understanding beyond previous literature, which often emphasized downstream signaling without integrating ERS modulation (see "Redefining Rapid Estrogen Signaling: G-1 (CAS 881639-98-1)" for a broad overview).

G-1 in Breast Cancer Research: Mechanisms of Migration Inhibition

GPR30-mediated signaling is increasingly implicated in tumor biology, particularly in estrogen receptor-positive and triple-negative breast cancers. G-1 has been demonstrated to inhibit the migration of breast cancer cell lines SKBr3 and MCF7 with remarkable potency (IC₅₀ values of 0.7 nM and 1.6 nM, respectively). Mechanistically, this effect is mediated via:

• Activation of rapid intracellular calcium signaling, leading to altered cytoskeletal dynamics and reduced motility.
• PI3K-dependent PIP3 accumulation, modulating key pathways involved in cell survival, migration, and invasion.

This positions G-1 as a valuable probe for dissecting non-genomic estrogen actions in breast cancer research, especially in contexts where conventional ER antagonists are ineffective or non-specific. While previous articles (e.g., "G-1: Selective GPR30 Agonist Accelerating Cardiovascular Research") have reviewed G-1’s utility in disease modeling, our focus on the mechanistic interplay between calcium and PI3K signaling in migration inhibition provides a deeper, more granular analysis.

Practical Considerations and Experimental Guidance

For researchers aiming to leverage G-1 in their studies, several practical factors warrant attention:

• Solubility and Storage: Prepare stock solutions in DMSO at concentrations >10 mM with warming and/or ultrasonic bath. Store at -20°C; avoid long-term storage for optimal activity.
• Experimental Concentrations: Use nanomolar to low micromolar concentrations for in vitro studies, taking advantage of G-1’s high potency and selectivity.
• Controls: Always include ERα, ERβ, and GPR30 antagonists to confirm receptor-specific effects, as demonstrated in mechanistic studies (Wang et al., 2021).
• Model Selection: G-1 is validated in a range of models, from cardiac fibrosis and heart failure to immune modulation and breast cancer cell migration.

APExBIO’s G-1 (B5455) offers researchers a rigorously characterized, high-purity reagent compliant with the demands of cutting-edge research in GPR30 signaling.

Conclusion and Future Outlook

The advent of G-1, a selective GPR30 agonist, has transformed the study of rapid estrogen signaling and its consequences in cardiovascular, endocrine, and cancer research. By providing unparalleled receptor specificity and robust in vitro and in vivo validation, G-1 enables the dissection of GPR30-mediated pathways with precision. This article has sought to bridge the gap between mechanistic insight and translational application, integrating advances in our understanding of intracellular calcium and PI3K signaling, ERS modulation, and disease modeling.

Looking ahead, further studies exploiting G-1 (CAS 881639-98-1), a selective GPR30 agonist, are likely to illuminate new therapeutic avenues for cardiac fibrosis attenuation, immune normalization post-injury, and the inhibition of breast cancer cell migration. By building upon and extending prior literature—including but not limited to broad overviews and disease-specific applications—this article offers a unified, mechanistically detailed resource for investigators at the forefront of G protein-coupled estrogen receptor research.